Clinical Trials Logo

Filter by:
NCT ID: NCT01098656 Terminated - Lymphoma Clinical Trials

Lenalidomide Maintenance Post-debulking in Advanced CTCL

Start date: July 2010
Phase: Phase 3
Study type: Interventional

RATIONALE: Observation is watching a patient's condition but not giving treatment unless symptoms appear or change. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is not yet known whether observation or lenalidomide is more effective in treating patients who are in complete or partial response after receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for cutaneous T-cell lymphoma or mycosis fungoides/Sézary syndrome. PURPOSE: This randomized phase III trial is studying observation to see how well it works compared with lenalidomide in treating patients who are in complete or partial response after receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for stage IIB, stage III, or stage IV cutaneous T-cell lymphoma or stage IIB, stage III, or stage IV mycosis fungoides/Sézary syndrome.

NCT ID: NCT01097707 Terminated - Clinical trials for Benign Prostatic Hyperplasia

A Study in Men With Benign Prostatic Hyperplasia

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)

NCT ID: NCT01096121 Terminated - Sickle Cell Disease Clinical Trials

Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children

MADREPIEC
Start date: June 2010
Phase: N/A
Study type: Interventional

Patients with sickle cell anaemia may develop renal disease. In fact, renal disease occurred in 40% of adults patients (macroalbuminuria) with evolution to end-stage renal disease for half of them. Microalbuminuria is an early and sensitive marker of glomerular damage. It appears during the first decade and occurred in 20 to 25% of infants (2 to 18 years). Physiopathology of renal scarring is not well understood actually. Renal scarring might be due to glomerular hyperfiltration and vascular and endothelial damage. Angiotensin-converting enzyme inhibitors (ACE) were studied and used in diabetic nephropathy. In a study on 26 sickle cell adults, albuminuria was reduced about 50% by ACE compared to placebo after six months treatment. It might be interesting studying ACE efficacy in sickle cell children with microalbuminuria because renal disease is directly related to sickle cell and is not influenced by other cardiovascular risk factors like in adult patients. We hypothesized to have a successful ACE treatment in more than 40% of cases after a nine months treatment period. A success is defined as a 50% reduction of the albuminuria/creatinuria ratio.

NCT ID: NCT01095250 Terminated - Uveitis Clinical Trials

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

INSURE
Start date: April 2010
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

NCT ID: NCT01095068 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Effects of Physical Exercise in Type 2 Diabetics

Start date: March 2010
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the improvement in skeletal muscle energetic capacity, endothelial dysfunction and glycemic control induced by physical training in 20 sedentary patients with a type 2 diabetes.The protocol consists in a physical training program with 3 sessions of 30 minutes per week during six consecutive weeks. A skeletal muscle biopsy, a cardiac and humeral artery ultrasounds, a glycemic and tensional holters will be performed before and at the end of the physical training program.

NCT ID: NCT01094067 Terminated - Clinical trials for Pulmonary Arterial Hypertension

Tezosentan in Patients With Pulmonary Arterial Hypertension

Start date: September 1, 2010
Phase: Phase 2
Study type: Interventional

Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a combination of both.

NCT ID: NCT01093846 Terminated - Uveitis Clinical Trials

38 Week Extension Study to CAIN457C2303

SHIELD
Start date: March 2010
Phase: Phase 3
Study type: Interventional

A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy

NCT ID: NCT01093066 Terminated - Clinical trials for Urothelial Carcinoma

Prospective Multicentric Evaluation of a Bladder Preservation Strategy

ReChiVe
Start date: September 21, 2010
Phase: Phase 2
Study type: Interventional

Radical cystectomy is the treatment of choice for bladder infiltrative urothelium carcinoma. But the removal of the bladder reservoir has a major impact of the Quality of life. Neoadjuvant chemotherapy has been shown to be associated with an absolute 5% survival benefit. Two monocentric studies suggest that this neoadjuvant chemotherapy could be used in combination with an optimal transurethral bladder resection, in a strategy of bladder preservation, provided a complete response being obtained (about 50% in every trial using neoadjuvant MVAC protocol before a radical cystectomy). In those both studies with patients T2 to T4, the 5 years overall survival is above 65%, with more than 40% bladder preservation rate at 5 years. The feasibility and the efficacy of such an attitude in a multicentric trail using the most active regimen (in term of complete response in metastatic patients) is unknown. The chosen regimen is therefore the intensified MVAC which allows, with the use of G-CSF, to double the dose-intensity of Adriamycin and Cisplatinum, and to decrease by 30% the methotrexate and vinblastine dose-intensity. The efficacy and safety confirmation of such an approach could lead to consider it in patients motivated to retain a functional bladder.

NCT ID: NCT01092312 Terminated - Clinical trials for Arthroplasty, Replacement, Knee

Signature Personalised Patient Care System With the Vanguard Knee System Study

Start date: March 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks is higher than those without the use of Signature when measured immediately post-operatively.

NCT ID: NCT01092052 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.